ADCT vs. AMRN, ANRO, HROW, CRBP, ERAS, MREO, RANI, TERN, MRSN, and ANNX
Should you be buying ADC Therapeutics stock or one of its competitors? The main competitors of ADC Therapeutics include Amarin (AMRN), Alto Neuroscience (ANRO), Harrow (HROW), Corbus Pharmaceuticals (CRBP), Erasca (ERAS), Mereo BioPharma Group (MREO), Rani Therapeutics (RANI), Terns Pharmaceuticals (TERN), Mersana Therapeutics (MRSN), and Annexon (ANNX). These companies are all part of the "pharmaceutical preparations" industry.
ADC Therapeutics (NYSE:ADCT) and Amarin (NASDAQ:AMRN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation, profitability and community ranking.
In the previous week, ADC Therapeutics had 6 more articles in the media than Amarin. MarketBeat recorded 8 mentions for ADC Therapeutics and 2 mentions for Amarin. Amarin's average media sentiment score of 1.37 beat ADC Therapeutics' score of 0.36 indicating that Amarin is being referred to more favorably in the news media.
Amarin has a net margin of -18.96% compared to ADC Therapeutics' net margin of -330.17%. Amarin's return on equity of -9.48% beat ADC Therapeutics' return on equity.
Amarin has higher revenue and earnings than ADC Therapeutics. Amarin is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.
ADC Therapeutics has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500. Comparatively, Amarin has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500.
ADC Therapeutics currently has a consensus target price of $7.25, indicating a potential upside of 75.54%. Amarin has a consensus target price of $1.08, indicating a potential upside of 15.75%. Given ADC Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe ADC Therapeutics is more favorable than Amarin.
Amarin received 791 more outperform votes than ADC Therapeutics when rated by MarketBeat users. Likewise, 74.45% of users gave Amarin an outperform vote while only 64.56% of users gave ADC Therapeutics an outperform vote.
41.1% of ADC Therapeutics shares are held by institutional investors. Comparatively, 22.3% of Amarin shares are held by institutional investors. 35.4% of ADC Therapeutics shares are held by insiders. Comparatively, 2.0% of Amarin shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Amarin beats ADC Therapeutics on 10 of the 18 factors compared between the two stocks.
Get ADC Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ADC Therapeutics Competitors List
Related Companies and Tools
